Overview

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a first in human study of ETD001 a new drug being developed for the treatment of cystic fibrosis. The study is a randomised, placebo-controlled, double-blind interventional study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of inhaled ETD001in healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Enterprise Therapeutics Ltd